WO2025002962 - USE OF A MPS1 INHIBITOR FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA
National phase entry is expected:
Publication Number
WO/2025/002962
Publication Date
02.01.2025
International Application No.
PCT/EP2024/067203
International Filing Date
20.06.2024
Title **
[English]
USE OF A MPS1 INHIBITOR FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA
[French]
UTILISATION D'UN INHIBITEUR DE MPS1 POUR LE TRAITEMENT DU CARCINOME HÉPATOCELLULAIRE
Applicants **
NERVIANO MEDICAL SCIENCES S.R.L.
Inventors
COLOMBO, Riccardo
GASPARRI, Fabio
TEXIDO ROMERO, Gemma
MARUZZELLI, Sara
Priority Data
23182638.9
30.06.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1897 | |
| EPO | Filing, Examination, Granting | 8699 | |
| Japan | Filing, Examination, Granting | 1964 | |
| South Korea | Filing, Examination, Granting | 1585 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
20,085
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention provides a low molecular weight ATP-competitive MPS1 inhibitor for use in the treatment of hepatocellular carcinoma (HCC).[French]
L'invention concerne un inhibiteur de MPS1 compétitif de l'ATP de faible poids moléculaire destiné à être utilisé dans le traitement du carcinome hépatocellulaire (HCC).